Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 30:2010:1504.

Lung cancer

Alan J Neville  1 , Mridula Sara Kuruvilla
Affiliations

Lung cancer

Alan J Neville et al. BMJ Clin Evid. .

Abstract

Introduction: Lung cancer is the leading cause of cancer deaths in both men and women, with 80% to 90% of cases caused by smoking. Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy. Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for resectable and unresectable non-small cell lung cancer? What are the effects of treatments for small cell lung cancer? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations, such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 96 systematic reviews and RCTs. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: chemotherapy (postoperative or preoperative, dose intensification), continuous hyperfractionated accelerated radiotherapy (CHART), first-line platinum (or non-platinum)-based chemotherapy, molecular-targeted therapy, non-CHART hyperfractionated radiotherapy, prophylactic cranial irradiation, second-line chemotherapy (with single agent), second-line molecular-targeted therapy (with gefitinib or erlotinib), and thoracic irradiation (with or without chemotherapy).

PubMed Disclaimer

References

    1. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(suppl 1):191–202. - PubMed
    1. Alam N, Darling G, Evans WK, et al. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol 2006;58:146–155. Search date 2005. - PubMed
    1. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473–483. - PubMed
    1. De Ruysscher D, Piljs-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543–552. Search date 2005. - PubMed
    1. Ihde DC, Pass HI, Glatstein E. Lung cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997:849–959.

Publication types

MeSH terms

LinkOut - more resources